Leaders in Pharmaceutical Business Intelligence (LPBI) Group

LIVE form Kresge Auditorium @MIT

Campturing key concepts;

• challenge of siRNA Delivery to Tumors of therapeutic cargo
• elevated pressure inside the tumor, penertarion of the rumor cell barrier is a challenge- undruggable
• reaching the tumor, tumor penetration, cytosolic translocation
• Tumor-penetrating peptides (R/KXXR/K and CendR)
• synthetic peptide activated penetration mechanism into tumor: LyP-1: CGNKRTRGC
• LyP-1 target p32 and penetrates tumors
• LyP-1 target p32 and penetrates tumors – stuck in the endososome
• Tandem peptide library
• myr-cell penetrating-tumor-specific + Cargo: siRNA
• cell pepetrating: polycationic CPP: TAT, VP22 and amphipathic:CPP
• Tandem Peptide (TPN) Sceen for knockdown and Receptor-Specific-Inhibition
• Characterization of binding and trafficking
• TPN – myr-TP-LyP-1
• Intracellular trafficking of TPN: penetrate tumor parenchyma in vivo: 1hr vs 3hrs: Extravascular accumulate cargo vs. intravascular does not
• Integrate structural and functional genomics @Broad Institute: 25 ovarian cell lines: ID4 is transforming, reccurrent amplified: In vitro validation of ID4 using TPNs
• Tumor Suppression by TPN/si/ID4 in vivo
• InVivo: Tumor Regression by TPN/si/ID4 – increased in mice survival sequences of ID4 plus penetration are need for survival
• TPN are not immuno-stimulatory
• Tumor regression and improved survival of mice: TPN/siPSMC2 (part of 26S pretase
• Tumor-Penetrating Nanoparticles in Pancreatic cancer: typical sequence of mutations: iRGD TPNs alphax integrin in stroma of tumor
• PEGylated TPNs deliver siRNA to PDA
• Modularity of Tandem Peptide Nanoparticles: macrophages, cancer tumor, bacteria,

10:30 – 11:00, 6/13/2014, Sangeeta Bhatia  “ Targeting siRNA delivery to tumors”

@MIT – Summer Symposium 2014: RNA Biology, Cancer and Therapeutic Implications, June 13, 2014 8:30AM – 4:30PM, Kresge Auditorium @MIT

http://ki.mit.edu/news/symposium

REALTIME event coverage for the Scientific Media by Dr.  A. Lev-Ari 

in Open Access Scientific Journal of Leaders in Pharmaceutical Business Intelligence (LPBI)

http://pharmaceuticalintelligence.com

#pharmaIT,#BIOIT,#technews,#curation,#pharmanews,#mobilehealth,#mhealth,#science,#science2_0,#healtcare,#BIOIT14,#Boston ,@Biotech News,@MhealthForAll,@mHealthAlliance,@HCtrends,@mobilehealth360,@science 2_0

Sangeeta Bhatia, MD, PhD 
John J. and Dorothy Wilson Professor of Health Sciences and Technology & Electrical Engineering and Computer Science, Massachusetts Institute of Technology
Director, Laboratory for Multiscale Regenerative Technologies, Koch Institute for Integrative Cancer Research
Investigator, Howard Hughes Medical Institute

Dr. Bhatia trained at Brown, MIT, Harvard, and MGH. She was a faculty member of the Bioengineering Department at University of California at San Diego for 6 years. She and her 150+ trainees (29 graduate, 25 postgraduate, 100+ undergraduate) have published more than 130 manuscripts that have collectively accumulated over 11,000 citations. She is the co-founder of two biotechnology startup companies, holds over 40 issued or pending patents in tissue engineering, biomedical microsystems, and nanobiotechnology and has worked in industry at Pfizer, Genetics Institute, ICI Pharmaceuticals, and Organogenesis. She co-authored the first undergraduate text on tissue engineering, as well a white paper about ‘convergence’ in life, physical and engineering sciences, highlighting the need for cooperation amongst research, economic and policy experts to advance biomedicine and healthcare. She is a frequent advisor to governmental organizations on nanobiotechnology, biomedical microsystems, and tissue engineering.

Dr. Bhatia has been recognized as one of the “the nation’s most promising young professors in science and engineering” by the David and Lucile Packard Foundation, one of the “100 most innovative young scientists worldwide” by MIT Technology Review, and has made top “Watch” lists at San Diego Magazine, The Scientist, andMass High Tech. Recently, she was named one of the “10 Most Influential Women in Biotech” by the Boston Globe. She received the NSF CAREER Award, the Global Indus Technovators Award, and Young Investigator Awards from the American Society of Mechanical Engineers, and the American College of Clinical Pharmacology. She is an elected Fellow of the Massachusetts Academy of Sciences, Biomedical Engineering Society, American Institute for Medical and Biological Engineering, and American Society for Clinical Investigation. Her work has been profiled broadly, such as in Scientific American and Popular Science, the Boston Globe, Forbes, PBS’s NOVA scienceNOW, Planet Green, and MSNBC.